[{"orgOrder":0,"company":"ATLAS PHARMS LLC","sponsor":"TME Pharma","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"","productType":"Small molecule","year":"2021","type":"Financing","leadProduct":"Emapticap pegol","moa":"CXCL12","graph1":"Oncology","graph2":"Phase II","graph3":"ATLAS PHARMS LLC","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"ATLAS PHARMS LLC \/ Atlas","highestDevelopmentStatusID":"8","companyTruncated":"ATLAS PHARMS LLC \/ Atlas"}]

Find Clinical Drug Pipeline Developments & Deals by Atlas Biologicals

Menu
Xls
Filters Filter
×
FILTER:
filter
Company Name
    filter

    Year

      filter

      DEALS // DEV.

        filter

        Country

          filter
          Sponsor
            filter

            Therapeutic Area

              filter

              Study Phase

                filter

                Deal Type

                  filter

                  Product Type

                    filter

                    Dosage Form

                      filter

                      Lead Product

                        filter

                        Target

                          Loading...

                          Therapeutic Area by Lead Product

                          Study Phase by Lead Product

                          Company by Lead Product

                          Top Deals by Deal Size (USD bn)

                          01

                          2024 ACI Convention
                          Not Confirmed
                          2024 ACI Convention
                          Not Confirmed

                          Details : As NOXXON advances its pipeline with upcoming start of clinical trials this additional liquidity will focus on manufacturing of NOX-A12 clinical trial supply in anticipation of upcoming clinical trials.

                          Brand Name : NOX-A12

                          Molecule Type : Small molecule

                          Upfront Cash : Undisclosed

                          June 01, 2021

                          Lead Product(s) : Emapticap pegol,Pembrolizumab,Irinotecan Hydrochloride

                          Therapeutic Area : Oncology

                          Highest Development Status : Phase II

                          Recipient : TME Pharma

                          Deal Size : Undisclosed

                          Deal Type : Financing

                          blank